Advanced Melanoma: CheckMate 067 10-Year Data Show Prognoses Transformed By Checkpoint Inhibitors

Sustained responses and long-term overall survival have resulted from checkpoint inhibitor therapy for advanced melanoma, transforming the prognosis for as many as half of patients. This is according to 10-year survival outcomes from the Phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma that were reported at the ESMO Congress 2024.   At the conference, Oncology Times reporter, Peter Goodwin, caught up with James Larkin, FRCP, PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.